U.S. markets close in 5 hours 20 minutes

BioXcel Therapeutics, Inc. (BTAI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.9499+0.1099 (+3.87%)
As of 10:39AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close2.8400
Bid2.9500 x 800
Ask2.9600 x 800
Day's Range2.8100 - 3.0000
52 Week Range2.8050 - 34.1250
Avg. Volume3,046,923
Market Cap86.335M
Beta (5Y Monthly)0.99
PE Ratio (TTM)N/A
EPS (TTM)-6.8700
Earnings DateNov 08, 2023 - Nov 13, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for BTAI

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • BioXcel Therapeutics, Inc.
    Analyst Report: Bristol-Myers Squibb Co.Bristol-Myers Squibb is a leading worldwide biopharmaceutical company. Its products focus on oncology, immunology and cardiovascular conditions. The company completed its merger with Celgene in November 2019. BMY shares are a component of the S&P 500.
    Fair Value
    Economic Moat
    5 days agoArgus Research
View more
  • Insider Monkey

    16 Most Shorted Stocks Right Now

    In this piece, we will take a look at the 16 most shorted stocks right now. If you want to skip our introduction to short selling, then take a look at 5 Most Shorted Stocks Right Now. One of the most intriguing plays on the stock market is short selling. This is because it goes […]

  • Zacks Small Cap Research

    BTAI: Strategic Reprioritization Underway...

    By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update Strategic Reprioritization Underway On August 14, 2023, BioXcel Therapeutics, Inc. (NASDAQ:BTAI) announced a strategic reprioritization that will impact a number of the areas of the business, including: • The commercial strategy for IGALMI will shift to focus more on the retail pharmacy and at-home setting and away

  • Motley Fool

    Why BioXcel Therapeutics Stock Flopped Again Today

    After the biotech's share price tanked on Monday on the back of less-than-inspiring quarterly results and the announcement of significant job cuts, it was hammered again the following day. As often happens in the wake of quarterly earnings reports that are either far better or substantially worse than expected, analysts adjusted their takes on BioXcel Tuesday. One prognosticator, Graig Suvannavejh of Mizuho Securities, went as far as to downgrade his recommendation on the stock.